Nasser K. Altorki, MD, on NSCLC: Adjuvant Atezolizumab for Stage IB–IIIA Disease

September 28, 2021 By The ASCO Post Staff

Nasser K. Altorki, MD, of Weill Medical College of Cornell University and NewYork-Presbyterian Hospital, discusses phase III data from the IMpower010 study, which showed that, compared with best supportive care, atezolizumab improved disease-free survival in patients with stage II–IIIA non–small cell lung cancer. These findings applied across most disease stages and most surgery types and chemotherapy regimens, as well as in patients with nodal involvement (Abstract PL02.05).

Related Content